evans blue has been researched along with Neuroendocrine Tumors in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Cheng, Y; Jacobson, O; Liu, Q; Sui, H; Wang, H; Zang, J; Zhu, Z | 1 |
| Buck, AK; Hänscheid, H; Hartrampf, PE; Lapa, C; Schirbel, A | 1 |
| Cai, W; Ehlerding, EB; Lan, X | 1 |
| Bandara, N; Chen, X; Jacobson, O; Mpoy, C; Rogers, BE | 1 |
1 trial(s) available for evans blue and Neuroendocrine Tumors
| Article | Year |
|---|---|
Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
Topics: Evans Blue; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Somatostatin | 2020 |
3 other study(ies) available for evans blue and Neuroendocrine Tumors
| Article | Year |
|---|---|
Intraindividual comparison of [
Topics: Evans Blue; Humans; Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Somatostatin | 2021 |
"Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics.
Topics: Albumins; Evans Blue; Humans; Neuroendocrine Tumors; Octreotide; Receptors, Somatostatin; Theranostic Nanomedicine | 2018 |
Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Evans Blue; Heterografts; Humans; Lutetium; Mice; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Theranostic Nanomedicine; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2018 |